PT Suparma Tbk (IDX:SPMA)

PT Suparma Tbk Ratios and Metrics

Market cap in millions IDR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 26, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	934,873	933,611	1,097,624	1,564,430	1,953,863	655,517
Market Cap Growth	2.21%	-14.94%	-29.84%	-19.93%	198.06%	-7.19%
Enterprise Value	1,480,552	1,306,734	1,522,871	2,070,731	2,519,139	1,235,541
Last Close Price	228.00	227.69	256.54	365.64	456.66	149.03
PE Ratio	16.01	8.90	6.14	4.65	6.64	4.03
PS Ratio	0.34	0.34	0.41	0.50	0.70	0.31
PB Ratio	0.38	0.39	0.47	0.73	1.08	0.43
P/TBV Ratio	0.38	0.39	0.47	0.73	1.08	0.43
P/FCF Ratio	1.48	1.39	1.68	1.82	2.62	1.02
P/OCF Ratio	1.39	1.31	1.60	1.70	2.47	0.94
EV/Sales Ratio	0.54	0.48	0.57	0.66	0.90	0.57
EV/EBITDA Ratio	4.72	4.37	4.33	3.36	5.11	3.83
EV/EBIT Ratio	8.73	6.87	5.97	3.94	6.10	5.39
EV/FCF Ratio	2.35	1.95	2.33	2.40	3.38	1.93
Debt / Equity Ratio	0.28	0.25	0.27	0.34	0.35	0.32
Debt / EBITDA Ratio	2.18	1.99	1.73	1.16	1.27	1.53
Debt / FCF Ratio	1.08	0.90	0.97	0.85	0.86	0.77
Net Debt / Equity Ratio	0.22	0.14	0.13	0.19	0.24	0.25
Net Debt / EBITDA Ratio	1.78	1.10	0.87	0.68	0.89	1.19
Net Debt / FCF Ratio	0.87	0.49	0.47	0.48	0.59	0.60
Asset Turnover	0.80	0.82	0.81	1.05	1.10	0.92
Inventory Turnover	2.35	2.68	2.63	3.42	4.66	4.24
Quick Ratio	0.48	1.01	1.10	1.40	0.92	0.68
Current Ratio	2.04	2.83	2.81	3.66	2.23	1.73
Return on Equity (ROE)	2.41%	4.46%	8.00%	16.97%	17.59%	11.17%
Return on Assets (ROA)	3.08%	3.55%	4.87%	10.98%	10.19%	6.11%
Return on Invested Capital (ROIC)	4.35%	5.56%	7.39%	17.00%	15.43%	9.94%
Return on Capital Employed (ROCE)	6.00%	6.60%	9.10%	18.40%	18.00%	11.80%
Earnings Yield	6.25%	11.23%	16.28%	21.49%	15.06%	24.79%
FCF Yield	67.39%	71.92%	59.67%	55.11%	38.12%	97.65%
Dividend Yield	-	-	3.60%	-	-	5.19%
Payout Ratio	-	36.02%	-	-	10.75%	-
Total Shareholder Return	-	-	3.60%	-	-	5.19%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.